Ultra-Fast-Track Cardiac Anesthesia(UFTCA)
Procedure(UFTCA)The researcher removed the endotracheal tube either immediately or within 1 hour of the end of the procedure.
NCT Number: NCT06541483
The goal of this clinical trial is to evaluate the clinical effects of ultra-fast-track anesthesia (UFTA) for minimally invasive cardiac surgery (MICS) in adults. It will also learn about the safety and feasibility of Ultra-Fast-Track cardiac surgery(UFTCA).The main questions it aims to answer are:Does UFTCA promote rapid postoperative recovery, reduce postoperative complications and perioperative mortality, and improve the quality of mid- and long-term survival.And does it improve patient satisfaction and reduce healthcare costs.
Participants will receive homogenized perioperative management in the cardiac ward, extracorporeal circulation, and postoperative ICU, except for anesthesia extubation time.Furthermore,Participants need complete quality of life scales at 30 days, 90 days, six months, and one year after surgery, separately.
Participants in this study are adults who required elective minimally invasive heart valve surgery under extracorporeal circulation.This study will be able to promote rapid recovery while reducing the associated costs and the financial burden on participants.Retrospective big data analysis of perioperative clinical characteristics of patients undergoing minimally invasive heart valve surgery to establish a risk warning model and develop a perioperative management program. The investigators then conducts a randomized group trial comparing the similarities and differences between conventional general anesthesia(CGA) and ultra-fast-track cardiac anesthesia(URTCA) to demonstrate the effectiveness and safety of UFTA in MICS.Finally, building expert consensus.
Trial opening soon.
Get Notified18 year–80 year
All sexes
Interventional
Not applicable
This study was divided into two parts:The first part is retrospective data collection and organization, screening risk factors to establish an early warning model to improve the perioperative management program, and the other part is conducted using a randomized controlled trial to evaluate the effectiveness, safety and benefit of the perioperative management program of ultra-fast-track anesthesia(UFTA) for minimally invasive heart valve surgery. The specific program is as follows:
Part I
Part II Recruitment of participants for a prospective randomized controlled trial
Anesthesia maintenance: Propofol injection 150~250 μg/(kg·min) and remifentanil 0.2~0.4 μg/(kg·min) were continuously pumped through the central venous catheter, and intraoperative EEG Bispectral Index (BIS) values were maintained between 40~60.
According to the hemodynamic indexes, respiratory parameters and the needs of surgical operation, intravenous sufentanil was injected in divided doses of 0.1~0.2 μg/kg, and the total amount of intraoperative sufentanil was controlled to be 1.0~1.5 μg/kg.
Additional rocuronium bromide 0.1~0.2 mg/kg was added at the time of aortic blockade and opening, respectively.
Intraoperative multimodal analgesia: (Pectoral nerves I(Pecs I), Pectoral nerves II(Pecs II), anterior serratus plane block(SPB)) anesthetic resuscitation: Evaluate to confirm whether the patient can be included in ultra-fast-track anesthesia.
After the aorta was opened, the anesthesiologist, by observing the surgical procedure and communicating with the surgeon as well as the sonographer in a timely manner, confirmed that the surgery was successful, the heart was restarting normally, the extracorporeal circulation was withdrawn smoothly, there was no active hemorrhage in the surgical field, hemostasis was complete, oxygenation was functioning well, and the patient's finger pulse oximetry saturation was ≥98% under conditions of inhaled pure oxygen.
UFTCA:The amount of propofol maintenance was dynamically adjusted according to the degree of stimulation at the beginning of chest closure, and all intravenous anesthesia maintenance drugs were discontinued at the beginning of chest closure. When the patient is under deep anesthesia, clear the patient's airway secretions and other foreign objects in advance; without interfering with the surgeon's operation, give bilateral lung bulging, and according to the trend of the BIS value and the patient's somatic reaction or not, give a single intravenous injection of propofol of 20~30mg as appropriate to maintain the patient's sedation until the end of the operation, and then remove the airway catheter when the patient is fully awake on the operating table. If necessary, an appropriate amount of neostigmine methylsulfate 1mg and atropine sulfate injection 0.5mg can be used intravenously to antagonize the muscle relaxant.
CGA:Propofol injection 150~250 μg/(kg·min) and remifentanil 0.2~0.4 ug/(kg·min) were continuously pumped, and the patients were transferred to the ICU with tubes, and the ICU doctors decided the timing of stopping sedation and extubation.
3.3 Postoperative multimodal analgesia Immediately after surgery, an intravenous analgesic pump was connected (sufentanil 200 μg and palonosetron 0.25 mg saline configured to a total of 200 mL)
Heparinization was performed at 3~4 mg/kg, and extracorporeal circulation was started after activated clotting time(ACT)>480s. The pacing fluid and dosage was 30 ml/kg, and the total amount did not exceed 2000 ml.
During extracorporeal circulation, the mean arterial pressure was maintained at 50~80 mmHg, and the perfusion flow rate was 2.2~2.4 L/m^2.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
(UFTCA)The researcher removed the endotracheal tube either immediately or within 1 hour of the end of the procedure.
(CGA)The researcher not extubated at the end of the operation and were admitted to the ICU under anesthesia with an endotracheal tube.
Time frame: From the end of the operation to the removal of the tracheal tube,up to 3 days
Time interval for tracheal extubation
Time frame: From entry to exit from ICU,approximately 3 days
Length of time participants stayed in the ICU
Time frame: From the end of surgery to discharge, approximately 1 week
Length of postoperative hospitalization
Time frame: From admission to discharge, approximately 2 weeks
Length of time participants stayed in the hospital
Time frame: From the end of surgery to 1 year after surgery
Acute kidney injury, coma, acute respiratory distress syndrome (ARDS), postoperative atrial fibrillation, pericardial tamponade, gastrointestinal complications, death, cardiac arrest, heart block, and permanent stroke
Time frame: From the end of surgery to 30 days after surgery
reintubation, reoperation,ICU readmission, 30-day readmission
Time frame: up to 1 year postoperative
minimum values:0 maximum values:100 higher scores mean a better outcome
Time frame: From admission to discharge, approximately 2 weeks
Total cost of treatment
Time frame: From end of surgery to removal from operating room, up to 1 hour
Time from end of surgery to removal from operating room
Time frame: intraoperative
Intraoperative dosage of sufentanil and remifentanil for induction and maintenance of anesthesia
Time frame: 72 hours post-surgery
minimum values:1 maximum values:10 higher scores mean a worse outcome
Time frame: From the end of surgery to discharge,approximately 1 week
Level of postoperative analgesia
Time frame: intraoperative
Vasoactive drugs given as per participant and intraoperative needs
Time frame: From admission to discharge, approximately 2 weeks
Pulmonary Function Assessment
Time frame: 24 hours post-surgery
Thoracic drainage within 24 hours after surgery
Time frame: From the end of surgery to chest drain removal, approximately 3 days
Total postoperative chest drainage
Time frame: From the end of surgery to chest drain removal, approximately 3 days
Thoracic drain removal time
Time frame: Time from end of surgery to first bowel evacuation, approximately 2 days
Assessment of postoperative recovery of gastrointestinal function
Time frame: Time from end of surgery to first time out of bed, approximately 2 days
First time out of bed
Time frame: From the start of anesthesia induction to 48 hours after extubation
interleukin(IL)-1β,IL-4,IL-6,IL-8,IL-10,Procalcitonin(PCT),Hypersensitive C-reactive protein(hs-CRP) and tumor necrosis factor(TNF)-α
Time frame: One day before to the next day after surgery,72 hours
Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), International Normalized Ratio (INR), Fibrinogen (FIB), D-dimer (DD2), Fibrin (Pro) Degradation Product (FDP), Antithrombin III (ATIII ), Thromboelastography (TEG)
Time frame: One day before to the next day after surgery,72 hours
N-terminal Pro-brain B-type Natriuretic Peptides(NT-proBNP), Cardiac troponin I(cTnI )
Time frame: One day before to the next day after surgery,72 hours
Neuron-specific enolase(NSE)
Time frame: Until 1 hours post-surgery
Costs incurred for perioperative anesthesia medications and anesthesia management requirements
Time frame: up to 1 year after discharge from hospital
Participants are rated on a 10-point satisfaction scale minimum values:1 maximum values:10 higher scores mean a better outcome
Contact information is provided by the study sponsor or research team.
Han W Wei, secretary
CONTACT
Mei J Yan, QC
CONTACT
Zhejiang Provincial People's Hospital
Other
A Multicenter Clinical Study of Ultra-Fast-Track Cardiac Anesthesia in Minimally Invasive Cardiac Surgery for Valvular Heart Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07721584
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT07687485
Cardiovascular Diseases, Cardiovascular Diseases (CVD)
View Trial DetailsNCT06458907
Cardiovascular Diseases, Heart Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT07684313
Cardiovascular Diseases, Heart Diseases
Carmel, Indiana, United States
View Trial Details